Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion
Monitoring BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a widely adopted method to assess response to therapy. However, a small minority of Ph+ ALL patients express variant BCR-ABL1 transcript types, usually due to splicing of...
Saved in:
Main Authors: | Mireille Crampe, Laura Kearney, David O’Brien, C. Larry Bacon, Derville O’Shea, Stephen E. Langabeer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/9635070 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
by: Alessandro Morotti, et al.
Published: (2015-01-01) -
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia
by: Mireille Crampe, et al.
Published: (2017-01-01) -
Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
by: Aytan Shirinova
Published: (2024-03-01) -
Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
by: Stephen E. Langabeer, et al.
Published: (2023-01-01)